RGX 501

Drug Profile

RGX 501

Alternative Names: Adeno-Associated Viral Vector Expressing Low-Density Lipoprotein Receptor

Latest Information Update: 15 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator REGENXBIO
  • Developer REGENXBIO; University of Pennsylvania
  • Class Antihyperlipidaemics; Gene therapies; Proteins
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hyperlipoproteinaemia type IIa
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Hyperlipoproteinaemia type IIa

Most Recent Events

  • 01 Mar 2017 REGENXBIO and University of Pennsylvania initiate enrolment in a phase I/II trial for Hyperlipoprotenaemia type IIa in USA (REGENXBIO, 10-K, March 2017)
  • 16 Feb 2017 ARIAD Pharmaceuticals has been acquired by Takeda
  • 05 Jul 2016 Phase-I/II clinical trials in Hyperlipoproteinaemia type IIa in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top